Uncategorized
Ranibizumab reduces leakage after macular telangiectasia, offers modest BCVA improvement
Although ranibizumab injections helped reduce leakage secondary to macular telangiectasia type 2, improvements in best corrected visual acuity were similar to those seen in the untreated fellow eye, according to study findings.The study included 10 eyes of 10 patients with bilateral macular telangiectasia without subretinal neovascularization. Eyes were randomly assigned to injection with 0.3 mg Lucentis (ranibizumab, Genentech) or 0.5 mg ranibizumab in only one eye. Injections were given at baseline, 1 month and 2 months; additional injections at months 3, 4 and 5 were given at the discretion of (Read more...)